PMID- 32683650
OWN - NLM
STAT- MEDLINE
DCOM- 20211210
LR  - 20211214
IS  - 1476-3524 (Electronic)
IS  - 1029-8428 (Linking)
VI  - 39
IP  - 2
DP  - 2021 Apr
TI  - Exploring the Neuroprotective Potential of Rosiglitazone Embedded Nanocarrier 
      System on Streptozotocin Induced Mice Model of Alzheimer's Disease.
PG  - 240-255
LID - 10.1007/s12640-020-00258-1 [doi]
AB  - Alzheimer's disease (AD) is a neurodegenerative disorder imposing great threat to 
      an individual's cognitive capability. Mounting evidence suggests that type 2 
      diabetes mellitus (T2DM) and AD is closely associated with impaired insulin 
      signalling and glucose metabolism in the brain. Member of the peroxisome 
      proliferator-activated receptor (PPAR) family, especially PPARgamma agonists, has 
      been well known for their insulin-sensitizing actions, but due to low water 
      solubility, poor penetration into the brain and associated toxicity limit their 
      use clinically. Therefore, this study has been undertaken to investigate the 
      neuroprotective potential of rosiglitazone embedded nanocarrier system on 
      streptozotocin (STZ) induced mice model of AD. In vitro neuroprotective efficacy 
      of rosiglitazone was determined on SH-SY5Y cells by assessing the messenger 
      ribonulceic  acid (mRNA) expression level of genes implicated for cognitive 
      function. AD in mice was developed by intracerebroventricular (ICV) 
      administration of STZ (3 mg/kg) directly into the lateral ventricles of the mice 
      brain. The cognitive parameters and mRNA expression levels were evaluated after 
      treatment with the free form of rosiglitazone as well as its nano-formulated 
      form. It was observed that rosiglitazone elicits neuroprotection on SH-SY5Y cells 
      as evidenced from the upregulation of genes such as cyclic-AMP response 
      element-binding protein (CREB), brain-derived neurotrophic factor (BDNF), glial 
      cell derived neurotrophic factor (GDNF), and nerve growth factor (NGF), which are 
      involved in cognitive functions. Further, the nano-formulated 
      rosiglitazone induced better neuroprotective efficacy than its free drug 
      treatment on animal model of AD as evidenced by attenuating the behavioural and 
      cognitive abnormalities, oxido-nitrosative stress and pro-inflammatory cytokines, 
      i.e. tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6a) along with 
      improved antioxidant enzymes (superoxide dismutase (SOD), reduced glutathione 
      (GSH), acetylcholine, neuronal density and expression of CREB, BDNF, GDNF and NGF 
      in the hippocampal region. Based on the results, it can be concluded that 
      rosiglitazone nanoformulation exerts strong neuroprotection via increasing the 
      mRNA expression of growth factors and inhibition of oxidative stress, and 
      neuroinflammation eventually prevents neuronal injury in AD.
FAU - K C, Sarathlal
AU  - K C S
AD  - Neuropsychopharmacology Division, Department of Pharmacy, Birla Institute of 
      Technology and Science, Pilani, Rajasthan, 333031, India.
FAU - Kakoty, Violina
AU  - Kakoty V
AD  - Neuropsychopharmacology Division, Department of Pharmacy, Birla Institute of 
      Technology and Science, Pilani, Rajasthan, 333031, India.
FAU - Marathe, Sandhya
AU  - Marathe S
AD  - Department of Cancer Biology, Birla Institute of Technology and Science, Pilani, 
      Rajasthan, 333031, India.
FAU - Chitkara, Deepak
AU  - Chitkara D
AD  - Neuropsychopharmacology Division, Department of Pharmacy, Birla Institute of 
      Technology and Science, Pilani, Rajasthan, 333031, India.
FAU - Taliyan, Rajeev
AU  - Taliyan R
AUID- ORCID: 0000-0003-2147-2990
AD  - Neuropsychopharmacology Division, Department of Pharmacy, Birla Institute of 
      Technology and Science, Pilani, Rajasthan, 333031, India. taliyanraja@gmail.com.
LA  - eng
GR  - SR/NM/NS-16/2015(G)/Department of Science and Technology, Ministry of Science and 
      Technology/
PT  - Journal Article
DEP - 20200718
PL  - United States
TA  - Neurotox Res
JT  - Neurotoxicity research
JID - 100929017
RN  - 0 (Neuroprotective Agents)
RN  - 05V02F2KDG (Rosiglitazone)
RN  - 5W494URQ81 (Streptozocin)
SB  - IM
MH  - Alzheimer Disease/*chemically induced/*drug therapy
MH  - Animals
MH  - Cell Line, Tumor
MH  - Disease Models, Animal
MH  - Drug Delivery Systems
MH  - Humans
MH  - Male
MH  - Neuroprotective Agents/*administration & dosage
MH  - Rosiglitazone/*administration & dosage
MH  - Streptozocin/*toxicity
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - Insulin resistance
OT  - Nanoformulation
OT  - Peroxisome proliferator activated receptor-gamma
OT  - Rosiglitazone
OT  - Streptozotocin
EDAT- 2020/07/20 06:00
MHDA- 2021/12/15 06:00
CRDT- 2020/07/20 06:00
PHST- 2020/05/06 00:00 [received]
PHST- 2020/07/13 00:00 [accepted]
PHST- 2020/07/06 00:00 [revised]
PHST- 2020/07/20 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2020/07/20 06:00 [entrez]
AID - 10.1007/s12640-020-00258-1 [pii]
AID - 10.1007/s12640-020-00258-1 [doi]
PST - ppublish
SO  - Neurotox Res. 2021 Apr;39(2):240-255. doi: 10.1007/s12640-020-00258-1. Epub 2020 
      Jul 18.